According to Alnylam Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -155.903. At the end of 2023 the company had a P/E ratio of -54.2.
Year | P/E ratio | Change |
---|---|---|
2023 | -54.2 | 111.97% |
2022 | -25.6 | 8.61% |
2021 | -23.6 | 35.01% |
2020 | -17.4 | 23.3% |
2019 | -14.1 | 46.71% |
2018 | -9.64 | -58.93% |
2017 | -23.5 | 200.45% |
2016 | -7.82 | -71.36% |
2015 | -27.3 | 44.59% |
2014 | -18.9 | -58.03% |
2013 | -45.0 | 412.48% |
2012 | -8.77 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() Arrowhead Pharmaceuticals
ARWR | -15.7 | -89.90% | ๐บ๐ธ USA |
![]() Regeneron Pharmaceuticals REGN | 12.6 | -108.08% | ๐บ๐ธ USA |
![]() Sarepta Therapeutics
SRPT | -14.4 | -90.74% | ๐บ๐ธ USA |
![]() OPKO Health
OPK | -26.9 | -82.75% | ๐บ๐ธ USA |
![]() Regulus Therapeutics RGLS | -11.1 | -92.90% | ๐บ๐ธ USA |
![]() Novartis NVS | 18.6 | -111.94% | ๐จ๐ญ Switzerland |
![]() Sanofi SNY | 17.5 | -111.24% | ๐ซ๐ท France |
![]() Teva Pharmaceutical Industries TEVA | -15.1 | -90.33% | ๐ฎ๐ฑ Israel |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.